Zai Lab Ltd. · HKEX:9688
Zai Lab — JP Morgan Healthcare Conference 2018
20 slides from Zai Lab's conference presentation, Jan 8, 2018
Slide 1: JP Morgan Healthcare Conference 2018
JP Morgan Healthcare Conference 2018 NASDAQ: ZLAB Exhibit 99.1
Slide 2: Disclaimer
Disclaimer This presentation includes forward-looking statements, beliefs or opinions, including statements with respect to our business, financial condition, results of operations and plans. These forward-looking statements involve known and unknown risks and uncertainties, many of which are beyond
Slide 3: Zai Lab – A China-based global innovative biopharma company
Zai Lab – A China-based global innovative biopharma company China-based global biopharma focusing on oncology, autoimmune & infectious diseases We are Developing innovative therapeutics to transform the lives of patients in China and worldwide Partnerships with leading biopharma companies such as Te
Slide 4: Recent highlights and anticipated upcoming milestones
Recent highlights and anticipated upcoming milestones 2017 highlights Exclusive license agreement with Paratek in Greater China $30M Series C Financing $172.5M US IPO on Nasdaq Dosing of first patient in Ph III registrational trial of ZL-2306 for Ovarian Cancer Exclusive license agreement with Five
Slide 5: Pioneering as the gateway to China, becoming a fully integrated global biopharma
Pioneering as the gateway to China, we envision Zai to become a fully integrated global innovative biopharma company Short term Mid-to-Long term Leading Chinese biopharmaceutical company Global fully integrated biopharmaceutical company Gateway to China Late-stage asset Early-stage asset Strong expe
Slide 6: Strong leadership team with experience in China and globally
Strong leadership team with experience and expertise in both China and globally Qi Liu M.D., Ph.D. Chief Medical Officer - Oncology Bo Zhang Ph.D. Vice President Head of CMC Minghui Chen Vice President Government & Regulatory Affairs Scientific advisory board Richard Flavell Ph.D., FRS Neal Rosen M.
Slide 7: Established R&D and manufacturing capabilities, with commercial infrastructure under construction
Established R&D and manufacturing capabilities, with commercial infrastructure under construction Manufacturing Facilities Manufacturing Leverage Government Incentives Research and Development Global and Local Know-how Commercial Sales Build Lean and Specialized Salesforce Robust Product Pipeline Co
Slide 8: Broad China and global product pipeline
Broad China and global product pipeline focusing on oncology, autoimmune and infectious diseases Program Indication Pre-clinical Phase 1 Phase 2 Phase 3/ pivotal Commercial rights Partner ZL-2306 Niraparib ZL-2401 Omadacycline FPA144 ZL-2301 Brivanib ZL-3101 Fugan ZL-2302 ZL-1101 China, HK, and Maca
Slide 9: Oncology pipeline to address unmet medical needs for Chinese oncology patients
Zai Lab’s oncology pipeline to address unmet medical needs for Chinese oncology patients Ovarian Cancer Liver Cancer Breast Cancer Lung Cancer Source: Cancer Facts & Figures 2015, American Cancer Society; Cancer Statistics in China, 2015, A Cancer Journal for Clinicians. Note: The data of both US an
Slide 10: Committed to solving the rising problem of antibiotic resistance in China
Zai also committed to contribute for solving the rapidly rising problem of antibiotic resistance in China China consumes half of the global antibiotics usage, which is over 160K tons, 48% are used in human Over 1 million pre-mature death due to MDR in China by 2050 Chinese government committed to de
Slide 11: Recent CFDA reform initiatives encourage innovation
Recent CFDA reform initiatives encourage innovation Accelerate the review and approval of new drug applications China Joins ICH Improve clinical trial infrastructure to encourage innovation Encourage China to join early global simultaneous development No CPP required for China NDA submission Conditi
Slide 12: Detailed updates of our progress
Detailed updates of our progress
Slide 13: ZL-2306 (Niraparib) development progressing well
ZL-2306 (Niraparib) development progressing well Achievements in 2017 Plan for 2018 Protocol discussions with CFDA for SCLC and breast cancer pivotal trials First-Patient-In for abbreviated ovarian pivotal trial in Sep. HK registration submitted Recruitment on track First-line ovarian treatment stud
Slide 14: ZL-2306: Expected to be the first local PARPi approved in China without biomarker test
ZL-2306 : Expected to be the first local PARPi approved in China without biomarker test Niraparib is favorably positioned in China amongst existing PARPs due to potential early market entry and best in class profile Source: Company filings, Evaluate Pharma, Broker research reports. Note: gBRCAm indi
Slide 15: 2017 accomplishments and 2018 milestones of other pipeline programs
Key 2017 accomplishments and anticipated 2018 milestone of other pipeline programs 2401 (Omadacycline) CTA submitted in late 2017 Category 1 status obtained Finalizing protocol with CFDA, expect first subject in 2H 2018 for the trial to enable approval 2301 (Brivanib) Phase II trial ongoing and recr
Slide 16: Five Prime collaboration reinforces Zai's strategic role in global drug development
Asset Five Prime collaboration reinforces Zai’s competitive advantage and strategic role in global drug development Deal structure Strategic value to Zai Next steps FPA 144 - Anti-FGFR2b antibody Gastric and GEJ cancer Global phase 3 planned to start in 2018 Strong proof of concept data in heavily p
Slide 17: Accelerating efforts to enhance integrated capabilities
Simultaneously accelerating efforts to enhance integrated capabilities Commercial Licensing & partnership Discovery Establish commercial organization in HK, Macau and mainland China To prepare for launch readiness, incl. market access strategy, pricing, etc. Continue licensing in quality assets Esta
Slide 18: Financial overview
Financial overview ~$240M cash at hand post IPO (pro-forma Sep. 2017), sufficient cash runway until at least end of 2019 Cash and Cash Equivalents ~100 headcount as of today; total 200+ headcount planned by end of 2018 Headcount
Slide 19: Our 2020 vision
Our 2020 vision : A leading China-based global innovative biopharma company 2+ products on market 3+ programs close to registration Multiple programs in research & development
Slide 20: Thank You
Thank You www.zailaboratory.com